R&D Shaping the future of immunodeficiency care, with Dr Jörg Sc... Dr Jörg Schüttrumpf, Chief Scientific Innovation Officer of Grifols, discusses advancing immunoglobulin (or IG) treatment for immune disorders.
Oncology Aligning with national efforts to modernise cancer diagnosti... Andrew Newland, former CEO of ANGLE, explains why live cell liquid biopsies should become standard in oncology.
Patients Rethinking prescription drug affordability, with Vinay Patel Vinay Patel, an innovative pharmacist, discuss the intricacies of drug pricing and accessibility in the US.
Digital An AI supercomputer and discovering next-gen brain disorder ... Tarek Samad, Lundbeck’s senior vice president and head of research, discusses AI – specifically, Lundbeck’s agreement with the DCAI to operate Gefion.
R&D On genomics, NGS, and doing much more good than bad, with Ma... Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.
Patients Delivering the right behavioural ingredients for the moment,... Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.
News J&J jumps on the MFN pricing train Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.